Integrative Health Solutions logoIntegrative HealthSOLUTIONS

Brain, Mood & Sleep

Pinealon / PE22‑28 / Selank

A three-peptide neurological protocol combining neuroprotective, neuroplasticity, and anxiolytic research profiles.

Woman meditating on a deck overlooking a misty lake
Format
Combination vial — injectable
Price
$240 per vial
Route
Nasal / Injectable
Evidence level
Preclinical
Regulatory status
Compounded
Testing
Provider Determines Testing

Pricing reflects the compounded preparation and doctor review. Final therapy and dosing are determined only after your intake is reviewed.

The components

Understanding the three components

Primarily preclinical research

Pinealon

Neuronal Stress-Response Research

A synthetic three-amino-acid peptide (Glu-Asp-Arg) studied mainly in cell and animal models of oxidative stress and neuronal injury. Researchers have examined how it affects cellular stress responses; these experimental findings are not proof of brain-protective effects in people.

Research focus

  • Reactive oxygen species and cell survival under experimental oxidative stress.
  • Neuronal stress resistance in laboratory models.
  • Learning-related outcomes in rat studies.

Important: Most supporting research is preclinical. Limited human reporting does not establish cognitive benefits or long-term safety, and findings on Pinealon alone do not establish the effects of this combination.

Preclinical research

PE22-28

TREK-1 Channel Research

A synthetic seven-amino-acid spadin analog investigated for inhibition of TREK-1, a potassium channel involved in regulating nerve-cell electrical activity. Published laboratory and mouse studies explore this channel as a target in mood-related research; they do not demonstrate a treatment effect in people.

Research focus

  • TREK-1 potassium-channel inhibition in engineered cell systems.
  • The relationship between channel activity and neuronal signaling.
  • Depression-related behavioral tests in mice.

Important: The identified primary evidence is preclinical. Antidepressant effects, cognitive benefits and safety in humans have not been established by these studies. Results for modified spadin analogs should not be assumed to apply to PE22-28 or this blend.

Preclinical / limited human research

Selank

Anxiety & Neurotransmission Research

A synthetic seven-amino-acid peptide investigated in small human studies of anxiety disorders and in animal studies of neurotransmission-related signaling. Research includes possible interactions with GABA-related pathways, which participate in the brain's inhibitory signaling; the mechanism and clinical relevance remain under investigation.

Research focus

  • Anxiety symptoms assessed in small comparative human studies.
  • GABA-related gene expression in rat brain tissue.
  • Possible modulation of neurotransmission-related signaling.

Important: Small comparative human studies do not establish broad effectiveness or long-term safety. Findings from individual Selank studies cannot establish the benefits, interactions or safety of this three-peptide preparation; disclose all psychiatric medications during doctor review.

How it works

How the combination is designed to work

Pinealon is a short peptide studied for neuronal protection, PE22-28 for neuroplasticity signaling, and Selank for anxiolytic activity — brought together in one compounded preparation.

  1. 01Research spans neuronal oxidative stress resistance (pinealon), TREK-1 channel modulation and synaptic plasticity (PE22-28), and GABAergic and serotonergic modulation (Selank).
Show illustration: Pinealon / PE22-28 / Selank
Pinealon / PE22-28 / Selank: proposed mechanism, physiology, and reported clinical effects. Educational illustration — not a treatment guarantee.

What has been studied

Potential applications and evidence

These areas are commonly discussed within wellness-focused protocols. They are educational statements, not medical claims or guarantees of outcome.

Explored for cognitive resilience
Discussed for mood and stress load
Potential neuroprotective interest
Used as a defined cycle with reassessment

Doctor-guided

A personalized approach

Your doctor determines the final testing requirements for Pinealon / PE22-28 / Selank after reviewing your intake. The panels below are what is commonly reviewed for this therapy — they are educational guidance, not a fixed requirement.

Bloodwork status: Provider Determines Testing

Commonly reviewed at baseline

  • CBC
  • Comprehensive metabolic panel (CMP)
  • Thyroid panel (TSH)
  • Vitamin B12

Follow-up & monitoring

Reviewed by cognitive, mood, and sleep response between cycles; labs repeated only if clinically indicated.

Medication review

Your doctor reviews all prescriptions, supplements, and over-the-counter medications during intake before anything is prescribed.

Format & dosing

Subcutaneous injection on a doctor-defined schedule, typically as a bounded cycle rather than continuous use.

Safety

What patients should know

  • Compounded, not FDA-approved. Evidence for these peptides is preliminary. Disclose all psychiatric medications during intake.

Who may not be a candidate

  • Pregnancy or nursing
  • Active malignancy without oncology clearance
  • Known hypersensitivity to the preparation
  • Uncontrolled psychiatric illness without co-management

Regulatory status: Compounded. Evidence level: Preclinical. Eligibility, dosing, laboratory requirements, and follow-up care are determined exclusively by a licensed doctor after review of your history.

Common questions

Frequently asked questions

Ready when you are

Find out what your body is actually asking for.

Fill out a short intake form and our care team will build a plan grounded in your labs — not a guess from a supplement aisle.